WeWork, Lord & Taylor, and the Artificial Separation of Work and Leisure

Posted by Ken Sawka on Nov 21, 2017 4:18:48 PM

One of my fondest memories growing up in New York was going into “the city” (that’s what we Long Islanders called Manhattan) at Christmastime and going to see the Lord & Taylor Christmas display in its storefront window at its flagship location on Fifth Avenue.  There would be long lines, and we’d wait 20 minutes or more just to get a glimpse of the window.  It was magical.

Read More

Topics: Sales Force Effectiveness, Brand Insights, Market Analysis, Merger and Acquisition, Product Positioning

Managing Regulatory and Political Risk

Posted by Robert Flynn on Nov 21, 2017 3:38:26 PM

In our paper The Global Economy’s New Frontiers, my colleague Nathaniel Emmons and I argue that when investing in emerging economies, companies can realize high returns but only if the risks are successfully managed. Transnational mining companies operating in Zimbabwe, for instance, are in crisis management mode following this month’s coup, impeachment of President Mugabe, and transfer of power to yet another strong-man. Not an unanticipated series of events given the political instability experienced in recent years, and something that needs intense effort to navigate.

Read More

Topics: Consumer Goods, Healthcare, Merger and Acquisition, Competitive Strategy, Early Warning

What’s Hindering the Broad Adoption of Value-Based Care?

Posted by Jacob Golbitz on Nov 21, 2017 12:51:51 PM

The public conversation about health care in this country may be driven by politics -- something we were reminded of last week when the Trump administration appeared to waffle on its latest attempt to undo the ACA. Beyond the political conversation, however, we find that professionals in payer and provider organizations are more focused on deeper layers of policy, technology, access to care and reimbursement. Those on the business end of the discussion are addressing key trends that are likely to continue regardless of the political discourse, whatever the current political climate.

Read More

Topics: Healthcare

CVS – Aetna: The Power of Strategic Competitive Analysis

Posted by Robert Flynn on Oct 27, 2017 2:46:39 PM

The Wall Street Journal and other sources revealed yesterday that pharmacy operator CVS Health Corporation has made an offer to acquire No. 3 health insurer Aetna Inc.  Wouldn’t it have been rewarding to have known the probability of such an acquisition?  Wouldn’t executives of Walgreens and Express Scripts or United Health Group and Anthem have benefited from an evaluation that showed the rationale for such an acquisition? Fuld + Company analysis produced in June 2017 did precisely that. Anticipating just such a move four months ago demonstrates of the power of competitive strategy.

Read More

Topics: Competitive Intelligence, War Games, Early Warning Monitoring, Healthcare, Competitive Strategy

Not Your Grandfather’s Gas Station:  Shell explores new technologies and business models at its gas station network in Europe

Posted by Diane Borska on Oct 26, 2017 2:47:27 PM

About a month ago, I was at a conference held in the motor city, also known as Detroit.  The conference topic was electrification and mobility with the discussion centered not on “if” the transportation sector was moving toward electrification but “when,” specifically, “how quickly.”

Read More

Topics: Energy and Utilities, strategic planning

Wearable Devices Provide a New Look for the Modern Clinical Trial

Posted by Premdharan Meyyan on Oct 24, 2017 10:34:40 AM

Clinical development has historically been a laborious and expensive process, driven by lengthy patient recruitment timelines, increasingly complex study designs, and high procedural costs, across different therapeutic areas. Additionally, a complex and dynamic regulatory framework has made it difficult to introduce new technologies to facilitate the development process. 

Read More

Topics: Market Analysis, Medical Devices, Life Sciences

The Electric Car You’ve Never Heard Of May Upend Tesla

Posted by Ray Tetreault on Oct 3, 2017 2:07:06 PM

To the casual observer, it may seem as if Tesla will be the end-all be-all for our future transportation needs. The reveal of the market-priced Model 3 earlier this year has led some to ring the victory bell, announcing Tesla as the unheralded king of electronic transportation. Not only will it be providing your residential vehicles, it will also be tackling the commercial and public transit sectors as well. Of course, there are other options out there; Nissan will be releasing its next-generation Leaf soon, Chevy continues to push its Bolt and Volt lines, and Volkswagen promises to have 30 electric models released as soon as 2025. Even China has its heavyweight in the mix, BYD, short for Build Your Dreams. Yet, you would be hard-pressed to find anyone who wouldn’t think of Tesla first and foremost when asked about electric transportation. However, viewing the playing field through the scope of competitive strategy exposes an entirely different conclusion.

Read More

Don’t Underestimate WeWork

Posted by Ken Sawka on Sep 20, 2017 3:28:18 PM

Co-Written by Robin Kao

Read More

Topics: Consumer Goods, Innovation, Competitive Strategy

Upcoming Event: FGH Academy of Competitive Intelligence Certification Program Boston October 23-27, 2017

Posted by Fuld + Company on Sep 19, 2017 3:58:14 PM

Join Leonard Fuld, Dr. Ben Gilad, and Ken Sawka in Boston, MA for their core certification courses. Competitive intelligence is not collecting random information. It's developing a skilled view of competitive risks and opportunities. Choose courses based on your interest or take all courses to become a certified CIP®.

Hotel discounted rate cut-off September 28, 2017

October registration October 23-27

Read More

Topics: Competitive Intelligence, Events, FGH Academy of Competitive Intelligence, Fuld, Leonard

Pharmaceutical Perspective: Considerations When Tapping into A New Market

Posted by Malini Solanki on Sep 14, 2017 10:15:52 AM

The U.S. is the largest market for pharmaceuticals, accounting for 30 to 40 percent of the worldwide market. However, newer smaller markets are on the rise for new drug products.

Read More

Topics: New Market Entry, Pharma

Fuld + Company Blog

The material on this page draws on the research and experience of Fuld + Company thought leaders, consultants and others. Learn more about our expertise here.

Recent Posts

Request for Information

If you'd like someone at Fuld to contact you regarding your strategic competitive challenges, fill out the form below.